Also known as: ACP-103; NUPLAZID
Pimavanserin is a selective serotonin 5-HT2A receptor inverse agonist/antagonist approved for treatment of Parkinson's disease psychosis (PDP). Manufactured by Mediocon Inc in Aurangabad, Maharashtra, India under GMP conditions, it is a novel antipsychotic without dopamine receptor activity. CAS No: 1231927-97-7.
| Parameter | Specification |
|---|---|
| CAS Number | 1231927-97-7 |
| Molecular Formula | C24H28Cl2N4OS |
| Molecular Weight | 491.48 g/mol |
| Grade | IP / BP / USP |
| Category | Atypical Antipsychotic / Serotonin Receptor Inverse Agonist |
| Appearance | White to off-white crystalline powder |
| Solubility | Freely soluble in methanol, slightly soluble in water, sparingly soluble in ethanol. |
| Assay | NLT 98.0% |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Residue on Ignition | NMT 0.1% |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Mfg Date | MAR 2026 |
| Exp Date | FEB 2031 |
| Packing | 25 kg HDPE drums / as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Pimavanserin — CAS 1231927-97-7 (CAS 1231927-97-7) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Pimavanserin — CAS 1231927-97-7 is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance